Algeta is a focused oncology company developing targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. These alpha-pharmaceuticals for the treatment of patients with cancer harness the unique characteristics of alpha particle emitters. The lead product is potent against cancer cells, remarkably well tolerated and convenient to use.
Algeta’s initial focus is on treating bone metastases, a serious clinical development of advanced cancer for which few specific treatments exist, and which represents an area of significant commercial potential.
The Company’s lead product, Alpharadin® (radium-223 chloride), is a first-in-class, targeted alpha-pharmaceutical that is in a global phase III clinical trial (ALSYMPCA) to treat bone metastases resulting from castration-resistant prostate cancer (CRPC).
In September 2009, Algeta entered into an $800 million agreement with Bayer Pharma AG for the development and global commercialization of Alpharadin® in prostate and other major cancers that frequently spread to bone.
The Company is headquartered in Oslo, Norway, and was founded in 1997 by Dr. Roy H. Larsen from the University of Oslo and Professor Øyvind S. Bruland, an oncologist at Rikshospitalet-Radiumhospitalet HF, a leading cancer research center.
Algeta listed on the Oslo Stock Exchange in March 2007 (Ticker: ALGETA).
No comments:
Post a Comment